InstitutionMD Anderson
DepartmentExperimental Therapeutics
Address1881 East Road
Houston TX 77054-3005
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002. PMID: 25427073; PMCID: PMC4266401.
      Citations: 20     Fields:    Translation:Humans
    2. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64. PMID: 25281606; PMCID: PMC4231417.
      Citations: 37     Fields:    Translation:Humans
    3. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36. PMID: 24614108; PMCID: PMC3973100.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    4. Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40. PMID: 24501394; PMCID: PMC4048124.
      Citations: 43     Fields:    Translation:HumansCells
    5. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659; PMCID: PMC4182922.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    6. Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66. PMID: 24024897; PMCID: PMC3860742.
      Citations: 17     Fields:    Translation:HumansCells
    7. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7. PMID: 23993427; PMCID: PMC4205589.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    8. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245; PMCID: PMC4180513.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    9. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. PMID: 23075701; PMCID: PMC4004358.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    10. Liu XJ, Nowak B, Wang YQ, Plunkett W. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug; 31(8):373-80. PMID: 22739266; PMCID: PMC3777512.
      Citations: 8     Fields:    Translation:AnimalsCells
    11. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    12. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19; 14(3):276-86. PMID: 22344033; PMCID: PMC3290742.
      Citations: 161     Fields:    Translation:HumansAnimalsCells
    13. Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs. 2012 Apr; 21(4):541-55. PMID: 22329458; PMCID: PMC3366487.
      Citations: 10     Fields:    Translation:HumansAnimals
    14. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 2012 Mar; 26(3):443-50. PMID: 21904380; PMCID: PMC3598158.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    15. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23. PMID: 21712425; PMCID: PMC3186292.
      Citations: 28     Fields:    Translation:HumansCells
    16. Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res. 2011 Jul 15; 17(14):4731-41. PMID: 21632856; PMCID: PMC5534342.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    17. Guo L, Liu X, Jiang Y, Nishikawa K, Plunkett W. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIa inhibitor. Mol Pharmacol. 2011 Aug; 80(2):321-7. PMID: 21546556; PMCID: PMC3141888.
      Citations: 9     Fields:    Translation:HumansCells
    18. Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar; 12(3):327-39. PMID: 21449673; PMCID: PMC3139433.
      Citations: 14     Fields:    Translation:Humans
    19. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010 Dec 16; 468(7326):927-32. PMID: 21164480; PMCID: PMC3058826.
      Citations: 205     Fields:    Translation:HumansCells
    20. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64. PMID: 20971952; PMCID: PMC3037741.
      Citations: 47     Fields:    Translation:HumansCells
    21. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010 Aug 15; 70(16):6587-97. PMID: 20663900; PMCID: PMC2929954.
      Citations: 16     Fields:    Translation:HumansCells
    22. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010 Jun 20; 28(18):3015-22. PMID: 20479412; PMCID: PMC4979218.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    23. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46. PMID: 20479284; PMCID: PMC2947394.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    24. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. PMID: 20421540; PMCID: PMC4872315.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    25. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12; 116(6):945-52. PMID: 20393129; PMCID: PMC4916575.
      Citations: 92     Fields:    Translation:HumansCells
    26. Chen R, Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2010 Mar; 23(1):155-66. PMID: 20620979.
      Citations: 8     Fields:    Translation:Humans
    27. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22. PMID: 21082931.
      Citations: 9     Fields:    Translation:Humans
    28. Abdel-Karim I, Plunkett WK, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs. 2011 Apr; 29(2):323-31. PMID: 20091088; PMCID: PMC4204658.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    29. Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem. 2010 Mar 12; 285(11):8022-30. PMID: 20064937; PMCID: PMC2832953.
      Citations: 6     Fields:    Translation:HumansCells
    30. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91. PMID: 19933907; PMCID: PMC3340938.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    31. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Gandhi V, Kay NE, Plunkett W, Burger JA, J?ger U. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485; PMCID: PMC4081374.
      Citations: 151     Fields:    Translation:HumansAnimalsCells
    32. Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, Lamba J. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics. 2009 Aug 15; 25(16):2013-9. PMID: 19528086; PMCID: PMC2723006.
      Citations: 9     Fields:    
    33. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA, R?ckert F, Gr?tzmann R. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009 Jun 12; 324(5933):1457-61. PMID: 19460966; PMCID: PMC2998180.
      Citations: 1481     Fields:    Translation:HumansAnimalsCells
    34. Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res. 2009 Jun 01; 15(11):3760-9. PMID: 19435836.
      Citations: 4     Fields:    Translation:HumansCells
    35. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45. PMID: 19234140; PMCID: PMC2680368.
      Citations: 79     Fields:    Translation:HumansCells
    36. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood. 2009 Apr 16; 113(16):3744-53. PMID: 19096009; PMCID: PMC2670791.
      Citations: 35     Fields:    Translation:HumansCells
    37. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5. PMID: 18932257; PMCID: PMC4126078.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    38. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008 Oct 27; 27(50):6522-37. PMID: 18955977.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    39. Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res. 2008 Oct 01; 68(19):7947-55. PMID: 18829552; PMCID: PMC2631429.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    40. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008 Sep 01; 112(5):1912-22. PMID: 18574029; PMCID: PMC2518893.
      Citations: 80     Fields:    Translation:HumansCells
    41. Wang Y, Liu X, Matsuda A, Plunkett W. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res. 2008 May 15; 68(10):3881-9. PMID: 18483273.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    42. Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 01; 14(9):2824-32. PMID: 18451250.
      Citations: 27     Fields:    Translation:AnimalsCells
    43. Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res. 2008 Oct; 32(10):1573-81. PMID: 18433867; PMCID: PMC4048126.
      Citations: 4     Fields:    Translation:Cells
    44. Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105. PMID: 18309944.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    45. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    46. Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther. 2008 Jan; 7(1):133-42. PMID: 18202016.
      Citations: 11     Fields:    Translation:HumansCells
    47. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA. miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37. PMID: 17927518.
      Citations: 47     Fields:    Translation:HumansAnimals
    48. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45. PMID: 17855478.
      Citations: 42     Fields:    Translation:HumansCells
    49. Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep. 2007 Sep; 9(5):361-7. PMID: 17706164.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    50. Guo L, Liu X, Nishikawa K, Plunkett W. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther. 2007 May; 6(5):1501-8. PMID: 17513599.
      Citations: 11     Fields:    Translation:HumansCells
    51. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther. 2007 Apr; 6(4):1239-48. PMID: 17406032.
      Citations: 90     Fields:    Translation:HumansCells
    52. Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P, Pelicano H. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006 Dec 18; 175(6):913-23. PMID: 17158952; PMCID: PMC2064701.
      Citations: 173     Fields:    Translation:HumansCells
    53. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66. PMID: 17108134.
      Citations: 30     Fields:    Translation:HumansCells
    54. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 Nov; 18(6):584-90. PMID: 16988579.
      Citations: 13     Fields:    Translation:Humans
    55. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006 Dec 15; 108(13):4187-93. PMID: 16954499; PMCID: PMC1895455.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    56. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7. PMID: 16818700.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    57. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006 Apr; 20(4):610-9. PMID: 16482209.
      Citations: 13     Fields:    Translation:HumansCells
    58. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):993-1000. PMID: 16543464; PMCID: PMC1895860.
      Citations: 101     Fields:    Translation:HumansCells
    59. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006 Mar 01; 106(5):1099-109. PMID: 16435387.
      Citations: 26     Fields:    Translation:Humans
    60. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603; PMCID: PMC1895741.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    61. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60. PMID: 16131572; PMCID: PMC1895256.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    62. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      Citations: 4     Fields:    Translation:Humans
    63. Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 2005 Aug 01; 65(15):6874-81. PMID: 16061671.
      Citations: 17     Fields:    Translation:HumansCells
    64. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9. PMID: 15972445; PMCID: PMC1895272.
      Citations: 116     Fields:    Translation:HumansCells
    65. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95. PMID: 15803490.
      Citations: 22     Fields:    Translation:Humans
    66. Khan SR, Nowak B, Plunkett W, Farquhar D. Bis(pivaloyloxymethyl) thymidine 5'-phosphate is a cell membrane-permeable precursor of thymidine 5'-phosphate in thymidine kinase deficient CCRF CEM cells. Biochem Pharmacol. 2005 May 01; 69(9):1307-13. PMID: 15826601.
      Citations: 4     Fields:    Translation:HumansCells
    67. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88. PMID: 15767648.
      Citations: 264     Fields:    Translation:HumansCTClinical Trials
    68. Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2005 Jun; 55(6):559-64. PMID: 15726370.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    69. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. PMID: 15496649.
      Citations: 12     Fields:    Translation:Humans
    70. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7. PMID: 15486072.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    71. Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23. PMID: 15571270.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    72. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42. PMID: 14695132.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    73. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003 Dec 08; 22(56):9063-74. PMID: 14663485.
      Citations: 57     Fields:    Translation:HumansCells
    74. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. PMID: 12921943.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    75. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9. PMID: 14551141.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    76. Yang LY, Jiang H, Rangel KM, Plunkett W. Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncol Rep. 2003 Sep-Oct; 10(5):1489-95. PMID: 12883729.
      Citations: 1     Fields:    Translation:HumansCells
    77. Rao VA, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res. 2003 Aug 01; 9(8):3204-12. PMID: 12912974.
      Citations: 8     Fields:    Translation:HumansCells
    78. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. PMID: 12885837.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    79. Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P, Pelicano H. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003 Sep 26; 278(39):37832-9. PMID: 12853461.
      Citations: 148     Fields:    Translation:HumansCells
    80. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86. PMID: 12791647.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    81. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    82. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003 May 15; 101(10):4098-104. PMID: 12531810.
      Citations: 113     Fields:    Translation:HumansCells
    83. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24. PMID: 12377965.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    84. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62. PMID: 12685828.
      Citations: 43     Fields:    Translation:Humans
    85. Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol. 2002 Sep; 62(3):680-8. PMID: 12181445.
      Citations: 15     Fields:    Translation:HumansCells
    86. Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002 Feb; 1(4):287-94. PMID: 12467224.
      Citations: 6     Fields:    Translation:HumansCells
    87. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002 Feb 01; 20(3):665-73. PMID: 11821446.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    88. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58. PMID: 12703199.
      Citations: 1     Fields:    Translation:HumansAnimals
    89. Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002 Jan; 61(1):222-9. PMID: 11752224.
      Citations: 7     Fields:    Translation:HumansCells
    90. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41(2):93-103. PMID: 11888330.
      Citations: 84     Fields:    Translation:HumansCells
    91. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res. 2001 Dec 15; 61(24):8723-9. PMID: 11751391.
      Citations: 32     Fields:    Translation:HumansCells
    92. Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol. 2001 Nov; 13(6):484-90. PMID: 11673689.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    93. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001 Nov; 7(11):3580-9. PMID: 11705880.
      Citations: 58     Fields:    Translation:HumansCells
    94. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9. PMID: 11481354.
      Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
    95. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer. 2001 Jul 01; 92(1):194-9. PMID: 11443627.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    96. Azuma A, Huang P, Matsuda A, Plunkett W. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol. 2001 Jun 15; 61(12):1497-507. PMID: 11377379.
      Citations: 7     Fields:    Translation:HumansCells
    97. Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15; 19(8):2142-52. PMID: 11304766.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    98. Azuma A, Huang P, Matsuda A, Plunkett W. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 2001 Apr; 59(4):725-31. PMID: 11259616.
      Citations: 33     Fields:    Translation:HumansCells
    99. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 2001 Feb 01; 61(3):1065-72. PMID: 11221834.
      Citations: 35     Fields:    Translation:HumansCells
    100. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45. PMID: 11686015.
      Citations: 15     Fields:    Translation:HumansAnimals
    101. Sampath D, Plunkett W. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res. 2000 Nov 15; 60(22):6408-15. PMID: 11103806.
      Citations: 4     Fields:    Translation:HumansCells
    102. Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy. 2000 Oct; 20(10):1204-7. PMID: 11034044.
      Citations: 1     Fields:    Translation:Humans
    103. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 Sep 21; 407(6802):390-5. PMID: 11014196.
      Citations: 193     Fields:    Translation:HumansCells
    104. Rodriguez CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30. PMID: 11043760.
      Citations: 9     Fields:    Translation:HumansCells
    105. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000 Aug; 14(8):1405-13. PMID: 10942236.
      Citations: 25     Fields:    Translation:HumansCells
    106. Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med. 2000 Jun; 5(6):597-604. PMID: 10812007.
      Citations: 9     Fields:    
    107. Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar; 18(5):995-1003. PMID: 10694549.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    108. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000 Mar; 6(3):773-81. PMID: 10741696.
      Citations: 15     Fields:    Translation:HumansCells
    109. Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem. 2000 Jan 07; 275(1):29-34. PMID: 10617581.
      Citations: 23     Fields:    Translation:HumansCells
    110. Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol. 2000; 46(5):382-6. PMID: 11127942.
      Citations: 10     Fields:    Translation:Humans
    111. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65. PMID: 10613450.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    112. Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma. 1999 Aug; 34(5-6):511-8. PMID: 10492074.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    113. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999 Jan 01; 59(1):107-14. PMID: 9892194.
      Citations: 27     Fields:    Translation:AnimalsCells
    114. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64. PMID: 9921974.
      Citations: 5     Fields:    Translation:HumansCells
    115. Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov; 16(11):3607-15. PMID: 9817282.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    116. Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998 Sep; 9(9):1003-8. PMID: 9818075.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    117. Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31. PMID: 9667246.
      Citations: 11     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    118. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood. 1998 Mar 01; 91(5):1742-8. PMID: 9473241.
      Citations: 11     Fields:    Translation:HumansCells
    119. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol. 1997 Nov; 52(5):798-806. PMID: 9351970.
      Citations: 13     Fields:    Translation:HumansCells
    120. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45. PMID: 9815841.
      Citations: 13     Fields:    Translation:HumansCells
    121. Huang P, Ballal K, Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res. 1997 Aug 15; 57(16):3407-14. PMID: 9270006.
      Citations: 8     Fields:    Translation:HumansCells
    122. Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55. PMID: 9815818.
      Citations: 9     Fields:    Translation:HumansCells
    123. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997 Jul 01; 90(1):270-8. PMID: 9207462.
      Citations: 27     Fields:    Translation:HumansCells
    124. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997 Apr 15; 57(8):1487-94. PMID: 9108450.
      Citations: 16     Fields:    Translation:HumansCells
    125. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91. PMID: 9137961.
      Citations: 3     Fields:    Translation:Humans
    126. Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74. PMID: 9137959.
      Citations: 1     Fields:    Translation:HumansAnimals
    127. Hunter NR, Brock WA, Hittelman WN, Plunkett W, Milas L, Gr?goire V. Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Radiat Res. 1996 Nov; 146(5):548-53. PMID: 8896581.
      Citations: 2     Fields:    Translation:Animals
    128. Plunkett W, Robertson B, Merle-Beral H, Mentz F, Hoffbrand AV, Panayiotidis P, Binet JL. What does apoptosis mean in CLL? Leuk Lymphoma. 1996 Oct; 22 Suppl 2:47-52. PMID: 9021708.
      Citations: 2     Fields:    Translation:Humans
    129. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996 Oct; 2(10):1731-41. PMID: 9816124.
      Citations: 18     Fields:    Translation:HumansCells
    130. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9. PMID: 8847890.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    131. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15. PMID: 8893876.
      Citations: 96     Fields:    Translation:HumansAnimals
    132. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996 Oct 01; 56(19):4453-9. PMID: 8813140.
      Citations: 21     Fields:    
    133. Plunkett W, Begleiter A, Liliemark JO, Reed JC. Why do drugs work in CLL? Leuk Lymphoma. 1996 Oct; 22 Suppl 2:1-11. PMID: 9021705.
      Citations: 2     Fields:    Translation:HumansAnimals
    134. Kamiya K, Huang P, Plunkett W. Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. J Biol Chem. 1996 Aug 09; 271(32):19428-35. PMID: 8702631.
      Citations: 6     Fields:    Translation:HumansCells
    135. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res. 1996 Jul 01; 56(13):3030-7. PMID: 8674058.
      Citations: 37     Fields:    Translation:HumansCells
    136. Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79. PMID: 8691580.
      Citations:    Fields:    Translation:Humans
    137. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8. PMID: 9816215.
      Citations: 12     Fields:    Translation:HumansCells
    138. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996 Apr 01; 156(7):2624-30. PMID: 8786328.
      Citations: 16     Fields:    Translation:Humans
    139. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar; 10(3):456-9. PMID: 8642861.
      Citations: 78     Fields:    Translation:HumansCells
    140. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64. PMID: 8547650.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    141. Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol. 1996; 37(5):445-50. PMID: 8599867.
      Citations: 13     Fields:    Translation:HumansCells
    142. Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8. PMID: 8646801.
      Citations:    Fields:    Translation:HumansCells
    143. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13. PMID: 8718419.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    144. Benvenuto JA, Hittelman WN, Zwelling LA, Plunkett W, Pandita TK, Farquhar D, Newman RA. Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol. 1995 Oct 12; 50(8):1157-64. PMID: 7488229.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    145. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995 Sep; 1(9):1005-13. PMID: 9816073.
      Citations: 14     Fields:    Translation:HumansCells
    146. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9. PMID: 7658710.
      Citations: 9     Fields:    Translation:Humans
    147. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10. PMID: 7481842.
      Citations: 218     Fields:    Translation:HumansAnimalsCells
    148. Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7. PMID: 7481847.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    149. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995 Aug; 22(4 Suppl 11):11-8. PMID: 7481839.
      Citations: 47     Fields:    Translation:AnimalsCells
    150. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995 Aug; 22(4 Suppl 11):19-25. PMID: 7481840.
      Citations: 39     Fields:    Translation:HumansCells
    151. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res. 1995 Jul 01; 55(13):2847-52. PMID: 7540950.
      Citations: 31     Fields:    Translation:HumansCells
    152. Ruifrok AC, Price RE, Brock WA, Hittelman WN, Plunkett WK, Ang KK, Gr?goire V. Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation. Radiother Oncol. 1995 Jul; 36(1):50-5. PMID: 8525025.
      Citations: 2     Fields:    Translation:AnimalsPHPublic Health
    153. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995 May; 47(5):1072-9. PMID: 7746274.
      Citations: 14     Fields:    Translation:HumansCells
    154. Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24. PMID: 7533664.
      Citations: 9     Fields:    Translation:AnimalsCells
    155. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78. PMID: 9815970.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    156. Xu YZ, Huang P, Plunkett W. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem. 1995 Jan 13; 270(2):631-7. PMID: 7822289.
      Citations: 9     Fields:    Translation:HumansCells
    157. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995; 36(3):181-8. PMID: 7781136.
      Citations: 38     Fields:    Translation:HumansCells
    158. Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN, Gr?goire V. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res. 1994 Dec 01; 54(23):6201-9. PMID: 7954467.
      Citations: 15     Fields:    Translation:AnimalsCells
    159. Hunter N, Brock WA, Milas L, Plunkett W, Hittelman WN, Gr?goire V. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):363-71. PMID: 7928463.
      Citations: 3     Fields:    Translation:Animals
    160. Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8. PMID: 8090026.
      Citations:    Fields:    Translation:HumansCells
    161. Wright SJ, Robertson LE, O'Brien S, Plunkett W, Keating MJ. The role of fludarabine in hematological malignancies. Blood Rev. 1994 Sep; 8(3):125-34. PMID: 7819814.
      Citations: 2     Fields:    Translation:Humans
    162. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug; 8(8):1269-74. PMID: 8057660.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    163. Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A, Pinkel D. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. J Clin Oncol. 1994 Mar; 12(3):587-95. PMID: 8120558.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    164. Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN, Gr?goire V. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res. 1994 Jan 15; 54(2):468-74. PMID: 8275483.
      Citations: 6     Fields:    Translation:Animals
    165. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6. PMID: 8174200.
      Citations: 4     Fields:    Translation:Humans
    166. Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83. PMID: 8204523.
      Citations: 2     Fields:    Translation:HumansCells
    167. Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol. 1994; 34(3):249-56. PMID: 8004759.
      Citations: 2     Fields:    Translation:HumansCells
    168. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39. PMID: 7510070.
      Citations: 5     Fields:    Translation:HumansAnimals
    169. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs. 1994; 47 Suppl 6:39-49. PMID: 7525188.
      Citations: 5     Fields:    Translation:Humans
    170. Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9. PMID: 7881348.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    171. Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24. PMID: 7544948.
      Citations: 2     Fields:    Translation:Humans
    172. Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8. PMID: 7525187.
      Citations: 2     Fields:    Translation:HumansAnimals
    173. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6. PMID: 7533576.
      Citations: 2     Fields:    Translation:Humans
    174. Xu YZ, Plunkett W. Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. J Biol Chem. 1993 Oct 25; 268(30):22363-8. PMID: 8226747.
      Citations: 2     Fields:    Translation:Cells
    175. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12. PMID: 8235690.
      Citations: 30     Fields:    Translation:Humans
    176. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20. PMID: 7694371.
      Citations: 1     Fields:    Translation:Humans
    177. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60. PMID: 8374873.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    178. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 01; 81(11):2878-84. PMID: 8499626.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    179. Kemena A, O'Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93. PMID: 8220117.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    180. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56. PMID: 8374523.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    181. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8. PMID: 8374522.
      Citations: 3     Fields:    Translation:Humans
    182. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993 Mar 01; 81(5):1146-51. PMID: 8382970.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    183. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50. PMID: 8394169.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    184. Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb; 20(1):50-63. PMID: 8475410.
      Citations: 10     Fields:    Translation:Humans
    185. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14. PMID: 8481660.
      Citations: 14     Fields:    Translation:Humans
    186. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993 Jan 01; 81(1):143-50. PMID: 8093345.
      Citations: 37     Fields:    Translation:HumansCells
    187. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia--correlation of response and survival. Leuk Lymphoma. 1993; 11 Suppl 2:167-75. PMID: 8124227.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    188. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24. PMID: 8418222.
      Citations: 64     Fields:    Translation:Humans
    189. Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma. 1993; 11 Suppl 2:71-4. PMID: 8124235.
      Citations: 2     Fields:    Translation:Humans
    190. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993; 10 Suppl:115-21. PMID: 8481661.
      Citations: 1     Fields:    Translation:Humans
    191. Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem. 1992 Nov 15; 207(1):163-7. PMID: 1489090.
      Citations: 6     Fields:    Translation:HumansCells
    192. Xu YZ, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1992 Nov 03; 44(9):1819-27. PMID: 1449536.
      Citations: 14     Fields:    Translation:HumansCells
    193. Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia. 1992 Nov; 6 Suppl 4:140-1. PMID: 1359203.
      Citations: 1     Fields:    Translation:Humans
    194. Claxton DF, Plunkett W, Andreeff M, Deisseroth AB. Retinoids and cancer therapy. J Natl Cancer Inst. 1992 Sep 02; 84(17):1306-7. PMID: 1495098.
      Citations: 2     Fields:    
    195. Kreis W, Budman DR. Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991. Cancer Res. 1992 Jul 01; 52(13):3818-20. PMID: 1617654.
      Citations:    Fields:    Translation:Humans
    196. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May; 10(5):790-4. PMID: 1373760.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    197. Sastry JK, Nehete PN, Khan S, Nowak BJ, Plunkett W, Arlinghaus RB, Farquhar D. Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol. 1992 Mar; 41(3):441-5. PMID: 1372082.
      Citations: 4     Fields:    Translation:HumansCells
    198. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992 Mar; 10(3):406-13. PMID: 1740680.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    199. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903. PMID: 1737352.
      Citations: 18     Fields:    Translation:HumansCells
    200. Yang SW, Huang P, Plunkett W, Becker FF, Chan JY. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem. 1992 Feb 05; 267(4):2345-9. PMID: 1310314.
      Citations: 19     Fields:    Translation:HumansCells
    201. Huang P, Farquhar D, Plunkett W. Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem. 1992 Feb 05; 267(4):2817-22. PMID: 1370834.
      Citations: 12     Fields:    Translation:HumansCells
    202. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992 Feb 01; 52(3):533-9. PMID: 1732039.
      Citations: 79     Fields:    Translation:HumansCells
    203. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia. 1992; 6 Suppl 2:78-80. PMID: 1578950.
      Citations: 1     Fields:    Translation:Humans
    204. Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7. PMID: 1458554.
      Citations: 4     Fields:    Translation:HumansCells
    205. Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992; 31(3):193-9. PMID: 1464155.
      Citations: 5     Fields:    Translation:HumansCells
    206. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991 Nov 15; 51(22):6110-7. PMID: 1718594.
      Citations: 227     Fields:    Translation:HumansCells
    207. Kemena A, Fernandez M, Bauman J, Keating M, Plunkett W. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta. 1991 Aug 30; 200(2-3):95-106. PMID: 1723357.
      Citations: 12     Fields:    Translation:Humans
    208. Huang P, Plunkett W. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol. 1991 Apr; 39(4):449-55. PMID: 1708088.
      Citations: 13     Fields:    Translation:Cells
    209. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991 Mar; 9(3):491-8. PMID: 1999720.
      Citations: 169     Fields:    Translation:HumansCTClinical Trials
    210. Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30. PMID: 1789190.
      Citations: 5     Fields:    Translation:HumansCells
    211. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991; 27(4):258-62. PMID: 1998982.
      Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
    212. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 1991; 49(3):239-68. PMID: 1675805.
      Citations: 24     Fields:    Translation:Humans
    213. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990 Nov 01; 50(21):6823-6. PMID: 2208147.
      Citations: 49     Fields:    Translation:HumansCells
    214. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17. PMID: 1699280.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    215. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol. 1990 Oct; 38(4):567-72. PMID: 2233693.
      Citations: 98     Fields:    Translation:HumansCells
    216. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem. 1990 Sep 25; 265(27):16617-25. PMID: 1697861.
      Citations: 57     Fields:    Translation:HumansCells
    217. Huang P, Farquhar D, Plunkett W. Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem. 1990 Jul 15; 265(20):11914-8. PMID: 1694849.
      Citations: 33     Fields:    Translation:HumansCells
    218. Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80. PMID: 2340517.
      Citations: 36     Fields:    Translation:HumansCells
    219. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia. 1990 Feb; 4(2):95-9. PMID: 2304361.
      Citations: 11     Fields:    Translation:Humans
    220. Keating MJ, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Transfus. 1990; 33:593-603. PMID: 2182449.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    221. Plunkett W, Heinemann V, Estey E, Keating M. Pharmacologically directed design of leukemia therapy. Haematol Blood Transfus. 1990; 33:610-3. PMID: 2182451.
      Citations: 2     Fields:    Translation:Humans
    222. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine). Cancer Invest. 1990; 8(2):313. PMID: 2400957.
      Citations: 8     Fields:    Translation:HumansAnimals
    223. Heinemann V, Plunkett W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol. 1989 Nov 15; 38(22):4115-21. PMID: 2688654.
      Citations: 11     Fields:    Translation:Cells
    224. Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5. PMID: 2478221.
      Citations: 11     Fields:    Translation:HumansCells
    225. Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8. PMID: 2479383.
      Citations: 3     Fields:    Translation:HumansCells
    226. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989 Jul; 74(1):19-25. PMID: 2473795.
      Citations: 65     Fields:    Translation:Humans
    227. Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol. 1989 May; 7(5):622-8. PMID: 2709090.
      Citations: 8     Fields:    Translation:Humans
    228. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res. 1989 Feb; 210(2):291-301. PMID: 2911256.
      Citations: 7     Fields:    Translation:AnimalsCells
    229. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82. PMID: 3165047.
      Citations: 9     Fields:    Translation:Humans
    230. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988 Jul 15; 48(14):4024-31. PMID: 3383195.
      Citations: 106     Fields:    Translation:AnimalsCells
    231. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34. PMID: 3335008.
      Citations: 28     Fields:    Translation:HumansCells
    232. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol. 1988; 22(3):205-10. PMID: 3165725.
      Citations: 7     Fields:    Translation:Humans
    233. Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production. Biochem Pharmacol. 1987 Sep 15; 36(18):2945-50. PMID: 3307790.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    234. Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43. PMID: 3478543.
      Citations: 14     Fields:    Translation:HumansCells
    235. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia. 1987 Aug; 1(8):580-3. PMID: 3669771.
      Citations: 22     Fields:    Translation:Humans
    236. Estey E, Keating MJ, Plunkett W, McCredie KB, Freireich EJ. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol. 1987 Jun; 14(2 Suppl 1):58-63. PMID: 3473684.
      Citations: 2     Fields:    Translation:Humans
    237. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol. 1987 Jun; 14(2 Suppl 1):159-66. PMID: 3589690.
      Citations: 28     Fields:    Translation:Humans
    238. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987 Jun 01; 47(11):3005-11. PMID: 3471322.
      Citations: 37     Fields:    Translation:Humans
    239. Plunkett W, Nowak B, Keating MJ. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep. 1987 May; 71(5):479-83. PMID: 3567973.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    240. Gandhi V, Danhauser L, Plunkett W. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23; 413:293-9. PMID: 3558682.
      Citations: 6     Fields:    Translation:HumansCells
    241. Plunkett W, Novotn? L. 5'-Fluorosulfonylbenzoyl derivatives of therapeutic nucleoside analogs. Nucleic Acids Symp Ser. 1987; (18):81-3. PMID: 3697156.
      Citations:    Fields:    Translation:HumansCells
    242. Plunkett W, Grindey GB. Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser. 1987; (18):77-9. PMID: 3697155.
      Citations: 2     Fields:    Translation:Animals
    243. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep; 81(3):387-94. PMID: 3463209.
      Citations: 20     Fields:    Translation:Humans
    244. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol. 1986 Jul; 4(7):1079-88. PMID: 3459811.
      Citations: 7     Fields:    Translation:Humans
    245. Saunders PP, Tan MT, Spindler CD, Robins RK, Plunkett W. 3-Deazaguanosine is metabolized to the triphosphate derivative in Chinese hamster cells deficient in hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1986 May 15; 261(14):6416-22. PMID: 3700397.
      Citations:    Fields:    Translation:AnimalsCells
    246. Shewach DS, Plunkett W. Cellular retention of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and the pattern of recovery of DNA synthesis in Chinese hamster ovary cells. Cancer Res. 1986 Apr; 46(4 Pt 1):1581-4. PMID: 2418951.
      Citations: 1     Fields:    Translation:AnimalsCells
    247. Liliemark JO, Plunkett W. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate. Cancer Res. 1986 Mar; 46(3):1079-83. PMID: 3484676.
      Citations: 14     Fields:    Translation:HumansCells
    248. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol. 1986; 18(2):145-52. PMID: 2431803.
      Citations: 24     Fields:    Translation:Humans
    249. Plunkett W, Iacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Scand J Haematol Suppl. 1986; 44:51-9. PMID: 3457439.
      Citations: 3     Fields:    Translation:Humans
    250. Plunkett W, Keating M. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C. Adv Exp Med Biol. 1986; 195 Pt B:171-5. PMID: 3766228.
      Citations:    Fields:    Translation:Humans
    251. Trkula D, Otsuka H, Plunkett W. Resistance to mutagenesis of cells biochemically transformed by herpesvirus DNA fragments. Biochem Biophys Res Commun. 1985 Dec 31; 133(3):1064-71. PMID: 3002361.
      Citations:    Fields:    Translation:HumansAnimalsCells
    252. Liliemark JO, Plunkett W, Dixon DO. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1985 Nov; 45(11 Pt 2):5952-7. PMID: 4053067.
      Citations: 18     Fields:    Translation:Humans
    253. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104. PMID: 3859935.
      Citations: 1     Fields:    Translation:Humans
    254. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985 Jun; 12(2 Suppl 3):20-30. PMID: 4012338.
      Citations: 30     Fields:    Translation:Humans
    255. Kuo MT, Plunkett W. Nick-translation of metaphase chromosomes: in vitro labeling of nuclease-hypersensitive regions in chromosomes. Proc Natl Acad Sci U S A. 1985 Feb; 82(3):854-8. PMID: 3856236; PMCID: PMC397145.
      Citations: 5     Fields:    Translation:AnimalsCells
    256. Plunkett W. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues. Ann N Y Acad Sci. 1985; 451:150-9. PMID: 3907452.
      Citations: 1     Fields:    Translation:HumansAnimalsCTClinical Trials
    257. Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol. 1984 Feb; 20(2):227-31. PMID: 6538488.
      Citations: 2     Fields:    Translation:Humans
    258. Plunkett W, Nowak B, Feun LG, Benjamin RS, Keating M, Freirich EJ. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia. Adv Exp Med Biol. 1984; 165 Pt B:345-50. PMID: 6372382.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    259. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol. 1983 Nov; 1(11):689-94. PMID: 6366130.
      Citations: 11     Fields:    Translation:Humans
    260. Avramis VI, Plunkett W. 2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine. Biochem Biophys Res Commun. 1983 May 31; 113(1):35-43. PMID: 6860342.
      Citations: 13     Fields:    Translation:AnimalsCells
    261. Avramis VI, Plunkett W. Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv. 1983; 1(1):1-10. PMID: 6085754.
      Citations: 4     Fields:    Translation:Animals
    262. Moore EC, Friedman J, Valdivieso M, Plunkett W, Marti JR, Russ J, Loo TL. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Biochem Pharmacol. 1982 Oct 15; 31(20):3317-21. PMID: 7150358.
      Citations: 2     Fields:    Translation:Humans
    263. Shewach DS, Plunkett W. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Cancer Res. 1982 Sep; 42(9):3637-41. PMID: 6179604.
      Citations: 2     Fields:    Translation:AnimalsCells
    264. Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res. 1982 Jul; 42(7):2587-91. PMID: 7083151.
      Citations: 15     Fields:    Translation:Animals
    265. Shewach DS, Plunkett W. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Biochem Pharmacol. 1982 Jun 01; 31(11):2103-9. PMID: 6180754.
      Citations:    Fields:    Translation:AnimalsCells
    266. Harris BA, Plunkett W. Termination of RNA by nucleotides of 9-beta-D-xylofuranosyladenine. Biochem Biophys Res Commun. 1982 May 31; 106(2):500-5. PMID: 6179518.
      Citations: 1     Fields:    Translation:AnimalsCells
    267. Plunkett W, Benjamin RS, Keating MJ, Freireich EJ. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. Cancer Res. 1982 May; 42(5):2092-6. PMID: 6175407.
      Citations: 7     Fields:    Translation:HumansCells
    268. Harris BA, Saunders PP, Plunkett W. Metabolism of 9-beta-D-xylofuranosyladenine by the Chinese hamster ovary cell. Mol Pharmacol. 1981 Jul; 20(1):200-5. PMID: 6270533.
      Citations: 2     Fields:    Translation:AnimalsCells
    269. Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res. 1981 Mar; 41(3):1227-35. PMID: 7459863.
      Citations: 5     Fields:    Translation:Humans
    270. Harris BA, Plunkett W. Biochemical basis for the cytotoxicity of 9-beta-D-xylofuranosyladenine in Chinese hamster ovary cells. Cancer Res. 1981 Mar; 41(3):1039-44. PMID: 6161693.
      Citations: 2     Fields:    Translation:AnimalsCells
    271. Plunkett W, Chubb S, Barlogie B. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1980 Dec 12; 221(2):425-30. PMID: 6938519.
      Citations: 1     Fields:    Translation:HumansCells
    272. Plunkett W, Chubb S, Alexander L, Montgomery JA. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 1980 Jul; 40(7):2349-55. PMID: 6966966.
      Citations: 22     Fields:    Translation:HumansCells
    273. Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1980 Mar; 40(3):588-91. PMID: 6937239.
      Citations: 14     Fields:    Translation:HumansCells
    274. Valdivieso M, Moore EC, Burgess AM, Marti JR, Russ J, Plunkett W, Loo TL, Bodey GP, Freireich EJ. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):285-92. PMID: 7407763.
      Citations: 1     Fields:    Translation:Humans
    275. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Loo TL. Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid. Cancer Res. 1979 Oct; 39(10):4119-22. PMID: 476649.
      Citations: 12     Fields:    Translation:Humans
    276. Plunkett W, Alexander L, Chubb S, Loo TL. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase. Cancer Res. 1979 Sep; 39(9):3655-60. PMID: 476690.
      Citations: 2     Fields:    Translation:AnimalsCells
    277. Shewach DS, Plunkett W. Effect of 2'-deoxycoformycin on the biologic half-life of 9-beta-D-arabinofuranosyladenine 5'-triphosphate in CHO cells. Biochem Pharmacol. 1979 Aug 01; 28(15):2401-4. PMID: 91375.
      Citations: 2     Fields:    Translation:AnimalsCells
    278. Plunkett W, Benvenuto JA, Stewart DJ, Loo TL. High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells. Cancer Treat Rep. 1979 Mar; 63(3):415-20. PMID: 284846.
      Citations:    Fields:    Translation:Humans
    279. Plunkett W, Alexander L, Chubb S, Loo TL. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Biochem Pharmacol. 1979; 28(2):201-6. PMID: 426835.
      Citations: 8     Fields:    Translation:AnimalsCells
    280. Plunkett W, Moner JG. UMP pyrophosphorylase of Tetrahymena pyriformis. Partial purification and properties. Arch Biochem Biophys. 1978 Apr 15; 187(1):264-71. PMID: 26316.
      Citations: 2     Fields:    Translation:Animals
    281. Plunkett W, Cohen SS. Penetration of mouse fibroblasts by 2'-deoxyadenosine 5'-phosphate and incorporation of the nucleotide into DNA. J Cell Physiol. 1977 May; 91(2):261-70. PMID: 558986.
      Citations: 3     Fields:    Translation:AnimalsCells
    282. Plunkett W, Cohen SS. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase. Ann N Y Acad Sci. 1977 Mar 04; 284:91-102. PMID: 280161.
      Citations: 2     Fields:    Translation:AnimalsCells
    283. Cohen SS, Plunkett W. The utilization of nucleotides by animal cells. Ann N Y Acad Sci. 1975 Aug 08; 255:269-86. PMID: 1059361.
      Citations: 5     Fields:    Translation:AnimalsCells
    284. Plunkett W, Cohen SS. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res. 1975 Jun; 35(6):1547-54. PMID: 1079475.
      Citations: 20     Fields:    Translation:AnimalsCells
    285. Plunkett W, Lapi L, Ortiz PJ, Cohen SS. Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA. Proc Natl Acad Sci U S A. 1974 Jan; 71(1):73-7. PMID: 4359332; PMCID: PMC387934.
      Citations: 11     Fields:    Translation:AnimalsCells
    286. Longo FJ, Plunkett W. The onset of DNA synthesis and its relation to morphogenetic events of the pronuclei in activated eggs of the sea urchin, Arbacia punctulata. Dev Biol. 1973 Jan; 30(1):56-67. PMID: 4735369.
      Citations: 2     Fields:    Translation:AnimalsCells
    287. Plunkett W, Moner JG. The role of uridine-cytidine kinase in the regulation of pyrimidine ribonucleotide synthesis in Tetrahymena pyriformis GL. Biochim Biophys Acta. 1971 Oct; 250(1):92-102. PMID: 4258867.
      Citations:    Fields:    Translation:AnimalsCells
    288. Introduction. Seminars in Oncology. 22:1-2.
    289. Inhibition of nucleic acid synthesis by 9-β-D-xylofuranosyladenine (XYL-A) is independent of cellular ribonucleotide pool levels.
    290. Metabolism of 9 β D arabinofuranosyladenine by mouse fibroblasts. Cancer Research. 35:415-422.
    291. ACS Symposium Series. 639:265-278.
    292. Cellular concentrations of dATP and ara-ATP in peripheral blood leukemic cells (PBC) and erythrocytes (RBC) from patients treated with deoxycoformycin (dCF) or arabinosyladenine (ara-A). 704.
    293. Apoptosis in chronic lymphocytic leukemia. Cancer Bulletin. 46:130-135.
    294. Rationale for the design of combination therapies that are active in T-cell lymphomas?. Haematologica Reports. 2:83-86.
    295. 2-fluoro-ATP. Federation Proceedings. 42.
    296. The effect of deoxycoformycin (dCF) on the toxicity and metabolism of 9-β-D-arabinofuranosyladenine (ARA-A) and its 5'-triphosphate (ARA-ATP) in CHO cells.
    297. DNA synthesis is essential for the expression of XYL-A toxicity in the CHO cell. 1071.
    298. Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe. Bioorganic and Medicinal Chemistry Letters.
    299. Potentiation of analogs of adenosine by an inhibitor of adenosine deaminase.
    300. Relationship between ARA-ATP concentration, DNA synthetic capacity (DSC) and viability in CHO cells. 1012.
    301. Mechanism-based drug combinations with the DNA strand-breaking nucleoside analog CNDAC. Molecular Cancer Therapeutics. 15:2302-2313.
    302. Response. Blood. 113:6499-6500.
    303. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia. Clinical Cancer Research. 22:3537-3549.
    304. In vivo cellular kinetics and pharmacology studies of ARA-C and 3-DAU chemotherapy for relapsing adult acute leukemia. Cell and Tissue Kinetics. 13:683.
    305. 2',2'-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides and Nucleotides. 8:775-785.
    306. Biochemical basis of the increased arabinosyladenine (ARA A) activity in the presence of adenosine deaminase inhibitors (ADI).
    307. Comparison of the metabolism, kinetics, and inhibitory action of arabinosyl-2-fluoroadenine (F-ara-A) and its 5'-monophosphate (F-ara-AMP) in tumor bearing mice.
    308. Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ARA-A) with 9-β-D-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells 9-β-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells.
    309. Preparation of 3-deazaguanosine[U-14C-ribosyl] and its metabolism by mammalian cells.
    310. Modulation of vidarabine metabolism by 2'-deoxycoformycin for therapy of acute leukemia. 23-27.
    311. Toxicity, metabolism and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-araA).
    312. Intracellular metabolism and action of an antitumor nucleoside, 2'-C- cyano-2'-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC). Nucleosides and Nucleotides. 16:1037-1039.
    313. Cellular pharmacodynamics as a guide to leukemia therapy. Cancer Bulletin. 46:8-14.
    314. Quantitation of DNA strand breaks in circulating blasts (CB) from leukemia patients during therapy with m-AMSA.
    315. Cellular pharmacology of arabinosylcytosine 5'-triphosphate (araCTP) in leukemic cells during high-dose araC therapy.
    316. Pharmacologically directed chemotherapy. Cancer Bulletin. 37:196-203.
    317. Modulation of arabinosyladenine metabolism by 2'- deoxycoformycin in the therapy of human acute leukaemia. Journal of Clinical Chemistry and Clinical Biochemistry. 20:407-408.
    318. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer Journal. 6.
    319. Oxaliplatin beim kolorektal-karzinom. Onkologie. 25:1-11.
    320. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 127:303-309.
    321. Gemcitabine. Nucleosides and Nucleotides. 16:1261-1270.
    322. Detection and quantitation of ARA-C 5'-triphosphate (ARA-CTP) in the leukemic cells of adult AML patients treated with ARA-C.
    323. Biochemical basis of the therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A). Pharmacologist. 23.
    PLUNKETT JR's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (753)
    Co-Authors (67)
    Similar People (60)
    Same Department Expand Description